logo
Plus   Neg
Share
Email

AstraZeneca: Phase III NEPTUNE Trial Of Imfinzi Fails To Meet Primary Goal

AstraZeneca plc (AZN.L,AZN) announced Wednesday final overall survival or OS results from the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in Stage IV non-small cell lung cancer or NSCLC.

In the trial, the combination of Imfinzi and tremelimumab did not meet the primary endpoint of improving OS, while safety and tolerability profile for the combination was consistent with previous trials.

The Phase III NEPTUNE trial was a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) in combination with tremelimumab, an anti-CTLA4 antibody, vs. standard-of-care or SoC platinum-based chemotherapy in previously-untreated Stage IV (metastatic) NSCLC patients.

The trial is being conducted in more than 200 centres across 29 countries, including the US, Europe, South and Central America, the Middle East and Asia.

The company noted that the trial was performed in an all-comers population. The primary analysis population was patients with a high tumour mutational burden or TMB, which is a measurement of the number of mutations within the genome of a tumour.

According to the company, in the primary analysis population of patients whose blood TMB was 20 or more mutations per megabase or mut/Mb, the combination of Imfinzi and tremelimumab did not meet the primary endpoint of improving OS compared to SoC chemotherapy.

José Baselga, Executive Vice President, Oncology R&D said, "We are fully committed to a deep analysis of the vast clinical and biomarker data from this trial to gain further insights to improve Immuno-Oncology approaches for patients with metastatic non-small cell lung cancer."

AstraZeneca plans to submit the full results for presentation at a forthcoming medical meeting.

Imfinzi is also being tested as monotherapy in the Phase III PEARL trial, and in combination with chemotherapy with or without tremelimumab in the Phase III POSEIDON trial. These are part of an extensive late-stage Immuno-Oncology programme in Stage IV NSCLC.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration on Tuesday unveiled a new international collaboration for simultaneous review and approval of cancer drugs along with the agency's Australian and Canadian counterparts. The simultaneous approval of cancer therapies by the three regulators is intended to accelerate the process of making these new treatments available to patients around the world. Humanscale Corp. recalled about 24,900 units of QuickStand Lite workstations for concerns of injury hazard. These include about 2,200 units sold in Canada. The recalled workstation's arm can break and cause the workstation to fall, posing a risk of injury. The company has already received 52 reports of the arm breaking, including 12 reports of minor injuries. Facebook has revealed more details on the structure of an independent "oversight board" that will make final decisions about what posts stay up or come down, even if the company disagrees. The new "Oversight Board" will govern appeals from both Facebook and its users.
Follow RTT